{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:00:56Z","timestamp":1785578456135,"version":"3.56.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007862","name":"California National Primate Research Center","doi-asserted-by":"publisher","award":["OD-011107"],"award-info":[{"award-number":["OD-011107"]}],"id":[{"id":"10.13039\/100007862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["RR-025063; AFT"],"award-info":[{"award-number":["RR-025063; AFT"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10928-026-10029-8","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:00:29Z","timestamp":1776790829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tracer kinetic modeling of a 14 kDa anti-CD8 PET tracer (2C8v144) for in vivo estimation of CD8 expression in tissue and blood, binding affinity, and total body receptor occupancy"],"prefix":"10.1007","volume":"53","author":[{"given":"Ruediger E.","family":"Port","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Andrew","family":"Boswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Marik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice F.","family":"Tarantal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Z.","family":"Ferl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"7528","key":"10029_CR1","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez A, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A (2014) Pd-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568\u2013571","journal-title":"Nature"},{"issue":"8","key":"10029_CR2","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde PS, Karanikas V, Evers S (2016) The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. Clin. Cancer Res. 22(8):1865\u20131874. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1507","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10029_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1158\/0008-5472.CAN-15-1707","volume":"76","author":"R Tavar\u00e9","year":"2016","unstructured":"Tavar\u00e9 R, Escuin-Ordinas H, Mok S, McCracken M, Zettlitz K, Salazar F, Witte O, Ribas A, Wu A (2016) An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy. Cancer Res. 76(1):73\u201382. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1707","journal-title":"Cancer Res."},{"key":"10029_CR4","unstructured":"Pandit-Taskar N, Postow M, O\u2019Donoghue J, Harding J, Ziolkowska M, Lyashchenko S, Lewis J, Wu A, Le W, Gudas J, Korn R, Torgov M, Wolchok J, Weber W (2018) First in human phase i imaging study with 89zr-iab22m2c anti cd8 minibody in patients with solid tumors. Journal of Nuclear Medicine. 59(supplement 1):596\u2013596. https:\/\/jnm.snmjournals.org\/content"},{"issue":"5","key":"10029_CR5","doi-asserted-by":"publisher","first-page":"720","DOI":"10.2967\/jnumed.121.262485","volume":"63","author":"MD Farwell","year":"2022","unstructured":"Farwell MD, Gamache RF, Babazada H, Hellmann MD, Harding JJ, Korn R, Mascioni A, Le W, Wilson I, Gordon MS, Wu AM, Ulaner GA, Wolchok JD, Postow MA, Pandit-Taskar N (2022) CD8-targeted PET imaging of tumor infiltrating t cells in patients with cancer: A Phase I first-in-human study of 89Zr-Df-IAB22M2C, a radiolabeled anti-CD8 minibody. J. Nucl. Med. 63(5):720\u2013726. https:\/\/doi.org\/10.2967\/jnumed.121.262485","journal-title":"J. Nucl. Med."},{"key":"10029_CR6","doi-asserted-by":"publisher","unstructured":"Ruijter KL, van de Donk P, Hooiveld-Noeken JS, Giesen D, Elias SG, Lub-de Hooge MN, Oosting SF, Jalving M, Timens W, Brouwers AH, Kwee TC, Gietema JA, Fehrmann RSN, Fine BM, Sanabria Boh\u00f3rquez SM, Yadav M, Koeppen H, Jing J, Guelman S, Lin MT, Mamounas MJ, Eastham JR, Kimes PK, Williams SP, Ungewickell A, de Groot DJA, de Vries EGE (2022) Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1\/2 trial. Nat Med. 28(12):2601\u20132610. https:\/\/doi.org\/10.1038\/s41591-022-02084-8","DOI":"10.1038\/s41591-022-02084-8"},{"issue":"10","key":"10029_CR7","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1158\/2326-6066.CIR-21-0405","volume":"10","author":"R Tavar\u00e9","year":"2022","unstructured":"Tavar\u00e9 R, Danton M, Giurleo JT, Makonnen S, Hickey C, Arnold TC, Kelly MP, Fredriksson F, Bruestle K, Hermann A, Ullman E, Edelmann KH, Potocky T, Dudgeon D, Bhatt NB, Doubrovin M, Barry T, Kyratsous CA, Gurer C, Tu N, Gartner H, Murphy A, Macdonald LE, Popke J, Mintz A, Griesemer A, Olson WC, Thurston G, Ma D, Kirshner JR (2022) Immuno-PET monitoring of lymphocytes using the CD8-specific antibody REGN5054. Cancer Immunol. Res. 10(10):1190\u20131209. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-0405","journal-title":"Cancer Immunol. Res."},{"key":"10029_CR8","doi-asserted-by":"crossref","unstructured":"De Groof, T.W.M., Lauwers, Y., De Pauw, T., Saxena, M., Vincke, C., Van Craenenbroeck, J., Chapon, C., Le Grand, R., Raes, G., Naninck, T., Van Ginderachter, J.A., Devoogdt, N.: Specific imaging of CD8+ T-Cell dynamics with a nanobody radiotracer against human CD8$$\\beta $$. Eur J Nucl Med Mol Imaging. 52, 193\u2013207 (2024) 10.1007\/s00259-024-06896-3","DOI":"10.1007\/s00259-024-06896-3"},{"issue":"26","key":"10029_CR9","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"S Neelapu","year":"2017","unstructured":"Neelapu S, Locke F, Bartlett N, Lekakis L, Miklos D, Jacobson C, Braunschweig I, Oluwole O, Siddiqi T, Lin Y, Timmerman J, Stiff P, Friedberg J, Flinn I, Goy A, Hill B, Smith M, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro J, Westin J, Chavez J, Ghobadi A, Komanduri K, Levy R, Jacobsen E, Witzig T, Reagan P, Bot A, Rossi J (2017) Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N. Engl. J. Med. 377(26):2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N. Engl. J. Med."},{"key":"10029_CR10","doi-asserted-by":"publisher","unstructured":"Wang Y, Wang C, Huang M, Qin S, Zhao J, Sang S, Zheng M, Bian Y, Huang C, Zhang H, Gu L, Jiang J, Xu C, Dai N, Zheng Y, Han J, Yang M, Xu T, Miao L (2022) Pilot study of a novel nanobody 68 Ga-NODAGASNA006 for instant PET imaging of CD8+ T cells. Eur J Nucl Med Mol Imaging 49:4394\u20134405. https:\/\/doi.org\/10.1007\/s00259-022-05903-9","DOI":"10.1007\/s00259-022-05903-9"},{"issue":"8","key":"10029_CR11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S, Aigner M, Rothe T, Minopoulou I, Tur C, Knitza J, Kharboutli S, Kretschmann S, Vasova I, Spoerl S, Reimann H, Munoz L, Gerlach R, Sch\u00e4fer S, Grieshaber-Bouyer R, Korganow A, Farge-Bancel D, Mougiakakos D, Bozec A, Winkler T, Kr\u00f6nke G, Mackensen A, Schett G (2024) CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. N. Engl. J. Med. 390(8):687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917","journal-title":"N. Engl. J. Med."},{"key":"10029_CR12","doi-asserted-by":"crossref","unstructured":"Innis, R., Cunningham, V., Delforge, J., Fujita, M., Gjedde, A., Gunn, R., Holden, J., Houle, S., SC, S.H., Ichise, M., Iida, H., Ito, H., Kimura, Y., Koeppe, R., Knudsen, G., Knuuti, J., Lammertsma, A., Laruelle, M., Logan, J., Maguire, R., Mintun, M., Morris, E., Parsey, R., Price, J., Slifstein, M., Sossi, V., Suhara, T., Votaw, J., Wong, D., Carson, R.: Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 27(9), 1533\u20131539 (2007) 10.1038\/sj.jcbfm.9600493","DOI":"10.1038\/sj.jcbfm.9600493"},{"issue":"3","key":"10029_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10928-013-9320-6","volume":"40","author":"K Varn\u00e4s","year":"2013","unstructured":"Varn\u00e4s K, Varrone A, Farde L (2013) Modeling of PET data in CNS drug discovery and development. J. Pharmacokinet Pharmacodyn. 40(3):267\u2013279. https:\/\/doi.org\/10.1007\/s10928-013-9320-6","journal-title":"J. Pharmacokinet Pharmacodyn."},{"issue":"4","key":"10029_CR14","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/cpt.2548","volume":"111","author":"A Varrone","year":"2022","unstructured":"Varrone A, Bundgaard C, Bang-Andersen B (2022) PET as a translational tool in drug development for neuroscience compounds. Clin. Pharmacol. Ther. 111(4):774\u2013785. https:\/\/doi.org\/10.1002\/cpt.2548","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10029_CR15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00259-022-05998-0","volume":"50","author":"S Sriraman","year":"2023","unstructured":"Sriraman S, Davies C, Gill H, Kiefer J, Yin J, Ogasawara A, Urrutia A, Javinal V, Lin Z, Seshasayee D, Abraham R, Haas P, Koth C, Marik J, Koerber J, Williams S (2023) Development of an 18F-labeled anti-human CD8 VHH for same-day immunoPET imaging. Eur. J. Nucl. Med. Mol. Imaging 50(3):679\u2013691. https:\/\/doi.org\/10.1007\/s00259-022-05998-0","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10029_CR16","doi-asserted-by":"crossref","unstructured":"Boyer, C., Auphan, N., Gabert, J., Blanc, D., Malissen, B., Schmitt-Verhults, A.-M.: Comparison of phosphorylation and internalization of the antigen receptor\/CD3 complex, CD8, and class I MHC-encoded proteins on T cells. Role of intracytoplasmic domains analyzed with hybrid CD8\/class I molecules. J Immunol. 143(6), 1905\u20131914 (1989) 10.4049\/jimmunol.143.6.1905. (Erratum in J Immunol 1990 Jan 1;144(1):408)","DOI":"10.4049\/jimmunol.143.6.1905"},{"key":"10029_CR17","unstructured":"Sriraman, S., Gill, H., Davies, C., Ogasawara, A., Oeh, J., Wang, X., Khosraviani, M., Berg, E., Tarantal, A.F., Koerber, J., Williams, S.: $$^{18}$$F-VHH5v3 for Same-Day Immuno-PET Imaging of human CD8. Manuscript in preparation"},{"key":"10029_CR18","doi-asserted-by":"crossref","unstructured":"Westermann, J., Pabst, R.: Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system? Immunol Today. 11, 406\u2013410 (1990) 10.1016\/0167-5699(90)90160-b","DOI":"10.1016\/0167-5699(90)90160-B"},{"key":"10029_CR19","doi-asserted-by":"crossref","unstructured":"Westermann, J., Pabst, R.: Distribution of lymphocyte subsets and natural killer cells in the human body. Clin Investig. 70, 539\u2013544 (1992) 10.1007\/BF00184787","DOI":"10.1007\/BF00184787"},{"issue":"7","key":"10029_CR20","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1023\/A:1018943613122","volume":"10","author":"B Davies","year":"1993","unstructured":"Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm. Res. 10(7):1093\u20131095","journal-title":"Pharm. Res."},{"key":"10029_CR21","doi-asserted-by":"crossref","unstructured":"Cleeren, F., Lecina, J., Ahamed, M., Raes, G., Devoogdt, N., Caveliers, V., McQuade, P., Rubins, D., Li, W., Verbruggen, A., Xavier, C., Bormans, G.: Al18F-Labeling Of Heat-Sensitive Biomolecules for Positron Emission Tomography Imaging. Theranostics. 7(11), 2924\u20132939 10.7150\/thno.20094.","DOI":"10.7150\/thno.20094"},{"key":"10029_CR22","doi-asserted-by":"crossref","unstructured":"Berg, E., Gill, H., Marik, J., Ogasawara, A., Williams, S., Dongen, G., Vugts, D., Cherry, S.R., Tarantal, A.F.: Total-Body PET and Highly Stable Chelators Together Enable Meaningful 89Zr-Antibody PET Studies up to 30 Days After Injection. J Nucl Med. 61(3), 453\u2013460. 10.2967\/jnumed.119.230961.","DOI":"10.2967\/jnumed.119.230961"},{"key":"10029_CR23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2165\/00003088-199733050-00001","volume":"33","author":"BJ Anderson","year":"1997","unstructured":"Anderson BJ, McKee AD, Holford NHG (1997) Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin. Pharmacokinet. 33:313\u2013327","journal-title":"Clin. Pharmacokinet."},{"key":"10029_CR24","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1126\/science.276.5309.122","volume":"276","author":"GB West","year":"1997","unstructured":"West GB, Brown JH, Enquist BJ (1997) A general model for the origin of allometric scaling laws in biology. Science 276:122\u2013126","journal-title":"Science"},{"key":"10029_CR25","unstructured":"Beal, S.L., Sheiner, L.B., Boeckmann, A.J., Bauer, R.J.: NONMEM 7.5 Users Guides. ICON plc, Gaithersburg, MD (1989\u20132020). https:\/\/nonmem.iconplc.com\/nonmem750"},{"key":"10029_CR26","doi-asserted-by":"crossref","unstructured":"Zhang L, Beal SL, Sheiner LB (2003) Simultaneous vs. sequential analysis for population PK\/PD data I: Best-case performance. J. Pharmacokin. Pharmacodyn. 30(6):387\u2013404","DOI":"10.1023\/B:JOPA.0000012998.04442.1f"},{"key":"10029_CR27","unstructured":"R Core Team: R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria (2022). R Foundation for Statistical Computing. https:\/\/www.R-project.org\/"},{"key":"10029_CR28","first-page":"575","volume-title":"Compstat 2002 - Proceedings in Computational Statistics","author":"F Leisch","year":"2002","unstructured":"Leisch F (2002) Dynamic generation of statistical reports using literate data analysis. In: Haerdle W, Roenz B (eds) Compstat 2002 - Proceedings in Computational Statistics. Physika Verlag, Heidelberg, Germany, pp 575\u2013580"},{"key":"10029_CR29","unstructured":"Leisch, F., R Core Team: Sweave User Manual. (2022). https:\/\/www.stat.ethz.ch\/R-manual\/R-devel\/library\/utils\/doc\/Sweave.pdf"},{"issue":"10","key":"10029_CR30","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s11095-005-6650-0","volume":"22","author":"DE Mager","year":"2005","unstructured":"Mager DE, Krzyzanski W (2005) Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm. Res. 22(10):1589\u20131596","journal-title":"Pharm. Res."},{"key":"10029_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/BF01371005","volume":"19","author":"LB Sheiner","year":"1991","unstructured":"Sheiner LB, Grasela T (1991) An introduction to mixed effect modeling: Concepts, definitions, and justification. J. Pharmacokin. Biopharm. 19:11\u201324","journal-title":"J. Pharmacokin. Biopharm."},{"key":"10029_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev.pa.32.040192.001153","volume":"32","author":"LB Sheiner","year":"1992","unstructured":"Sheiner LB, Ludden TM (1992) Population pharmacokinetics\/dynamics. Annu. Rev. Pharmacol. Toxicol. 32:185\u2013209","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10029_CR33","unstructured":"Port, R.: SOP 14: Population Pharmacokinetic Analysis. In: Gastl, G., Berdel, W., Edler, L., Jaehde, U., Port, R., Mross, K., Scheulen, M., Sindermann, H., Dittrich, C. (eds.) Standard Operating Procedures for Clinical Trials of the CESAR Central European Society for Anticancer Drug Research - EWIV. Karger GmbH, Freiburg. DOI: 10.1159\/000075017. Onkologie 26 (suppl. 6): 60-66, 2003. https:\/\/www.karger.com\/Article\/Pdf\/75017"},{"issue":"6","key":"10029_CR34","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1023\/A:1014414520282","volume":"28","author":"DE Mager","year":"2001","unstructured":"Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokin Pharmacodyn. 28(6):507\u2013532","journal-title":"J Pharmacokin Pharmacodyn."},{"key":"10029_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/antib4030141","volume":"4","author":"S Hoefman","year":"2015","unstructured":"Hoefman S, Ottevaere I, Baumeister J, Sargentini-Maier ML (2015) Pre-clinical intravenous serum pharmacokinetics of albumin binding and non-half-life extended Nanobodies\u00ae. Antibodies 4:141\u2013156","journal-title":"Antibodies"},{"key":"10029_CR36","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.4049\/jimmunol.139.10.3231","volume":"139","author":"S Takada","year":"1987","unstructured":"Takada S, Engleman EG (1987) Evidence for an association between CD8 molecules and the T cell receptor complex on cytotoxic T cells. J. Immunol. 139:3231\u20133235","journal-title":"J. Immunol."},{"key":"10029_CR37","doi-asserted-by":"publisher","unstructured":"Storek J, Lalovic BB, Rupert K, Dawson MA, Shen DD, Maloney DG (2002) Kinetics of B, CD4 T, and CD8 T cells infused into humans: estimates of intravascular:extravascular ratios and total body counts. Clin Immunol. 102:249\u2013257 https:\/\/doi.org\/10.1006\/clim.2001.5174","DOI":"10.1006\/clim.2001.5174"},{"key":"10029_CR38","doi-asserted-by":"publisher","unstructured":"Coulie PG, Karanikas V, Lurquin C, Colau D, Connerotte T, Hanagiri T, Van Pel A, Lucas S, Godelaine D, Lonchay C, Marchand M, Van Baren N, Boon T (2002) Cytolytic t-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol. Rev. 188(1):33\u201342. https:\/\/doi.org\/10.1034\/j.1600-065X.2002.18804.xhttps:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-065X.2002.18804.x","DOI":"10.1034\/j.1600-065X.2002.18804.x"},{"key":"10029_CR39","doi-asserted-by":"publisher","unstructured":"Trepel F (1974) Number and distribution of lymphocytes in man. A critical analysis. Klin Wochenschr. 52:511\u2013515. https:\/\/doi.org\/10.1007\/BF01468720","DOI":"10.1007\/BF01468720"},{"issue":"3","key":"10029_CR40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1046\/j.0902-4441.2003.00199.x","volume":"72","author":"LR Bisset","year":"2004","unstructured":"Bisset LR, Lung TL, Kaelin M, Ludwig E, Dubs RW (2004) Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland. Eur. J. Haematol. 72(3):203\u2013212","journal-title":"Eur. J. Haematol."},{"key":"10029_CR41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/B978-0-12-396962-0.00010-0","volume":"503","author":"KD Wittrup","year":"2012","unstructured":"Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ (2012) Practical theoretic guidance for the design of tumor-targeting agents. Meth Enzymol. 503:255\u2013268","journal-title":"Meth Enzymol."},{"key":"10029_CR42","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/(SICI)1522-2586(199909)10:3<233::AID-JMRI3>3.0.CO;2-M","volume":"10","author":"RE Port","year":"1999","unstructured":"Port RE, Knopp MV, Hoffman U, Milker-Zabel S, Brix G (1999) Multicompartment analysis of gadolinium chelate kinetics: Blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging. J. Magn. Reson. Imag. 10:233\u2013241","journal-title":"J. Magn. Reson. Imag."},{"key":"10029_CR43","doi-asserted-by":"crossref","unstructured":"Jain RK (1994) Barriers to drug delivery in solid tumors. Sci. Am. 42\u201349","DOI":"10.1038\/scientificamerican0794-58"},{"key":"10029_CR44","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/BF02648108","volume":"24","author":"RK Jain","year":"1996","unstructured":"Jain RK (1996) 1995 whitaker lecture: Delivery of molecules, particles, and cells to solid tumors. Ann Biomed Engineer. 24:457\u2013473","journal-title":"Ann Biomed Engineer."},{"key":"10029_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s002800050946","volume":"44","author":"R Port","year":"1999","unstructured":"Port R, Hanisch F, Becker M, Bachert P, Zeller J (1999) Local disposition kinetics of floxuridine after intratumoral and subcutaneous injection as monitored by $$^{19}$$F-nuclear magnetic resonance spectroscopy in vivo. Cancer Chemother. Pharmacol. 44:65\u201373","journal-title":"Cancer Chemother. Pharmacol."}],"updated-by":[{"DOI":"10.1007\/s10928-026-10055-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000}}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10029-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-026-10029-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10029-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:55:24Z","timestamp":1785578124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-026-10029-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10029"],"URL":"https:\/\/doi.org\/10.1007\/s10928-026-10029-8","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The text under the Results section '27% at the lowest dose and increased to 62% and 84%' has been corrected to '30% at the lowest dose and increased to 62% and 75%'. Figure 4 has been replaced with correct figure.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10928-026-10055-6","URL":"https:\/\/doi.org\/10.1007\/s10928-026-10055-6","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.E.P., C.A.B., A.O., H.G., J.M., S.P.W and G.Z.F. are current or former employees of Genentech. R.E.P., C.A.B., A.O., H.G., J.M., S.P.W and G.Z.F. are current or past stockholders in Genentech, a Roche company.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23"}}